Methods and Materials
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Human papillomavirus and rising oropharyngeal cancer incidence in the United States.J Clin Oncol. 2011; 29: 4294-4301
- Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades.Head Neck. 2016; 38: 743-750
- Human papillomavirus and survival of patients with oropharyngeal cancer.N Engl J Med. 2010; 363: 24-35
- Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.J Clin Oncol. 2010; 28: 4142-4148
- Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?.Clin Transl Radiat Oncol. 2018; 8: 4-11
- An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.J Clin Oncol. 2003; 21: 92-98
- Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.N Engl J Med. 2006; 354: 567-578
- Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab.J Clin Oncol. 2016; 34: 1300-1308
- Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck.J Natl Cancer Inst. 2019; 111: 490-497
- Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002).J Clin Oncol. 2021; JCO2003128
- Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: A systematic review and meta-analysis of aggregate data.Oncologist. 2017; 22: 1056-1066
- Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma.Head Neck. 2016; 38: E1117-E1121
- Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.J Clin Oncol. 2013; 31: 543-550
- AJCC Cancer Staging Manual.8th ed. Springer International Publishing: American Joint Commission on Cancer, New York, NY2017
- Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): A multicentre cohort study.Lancet Oncol. 2016; 17: 440-451
- Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma.Br J Cancer. 2015; 112: 1098-1104
- The M. D. Anderson Symptom Assessment Inventory (MDASI) Users Guide.2010 (Available at:)https://www.mdanderson.org/content/dam/mdanderson/documents/Departments-and-Divisions/Symptom-Research/MDASI_userguide.pdf(Accessed May 23, 2021)
- Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module.Head Neck. 2007; 29: 923-931
- The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. A study of utility and validity.Cancer. 1996; 77: 2294-2301
- The hospital anxiety and depression scale.Acta Psychiatr Scand. 1983; 67: 361-370
- The Hearing Handicap Inventory for Adults: Psychometric adequacy and audiometric correlates.Ear Hear. 1990; 11: 430-433
- Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials.J Biopharm Stat. 2004; 14: 73-96
- Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.Med Care. 2003; 41: 582-592
- Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial - A Trans-Tasman Radiation Oncology Group study.Oral Oncol. 2020; 110104988
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial.Lancet. 2018; 393: 40-50
- Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial.Lancet. 2018; 393: 51-60
- A longitudinal study of distress (depression and anxiety) up to 18 months after radiotherapy for head and neck cancer.Psychooncology. 2013; 22: 1843-1848
- How standard is second-line cetuximab in recurrent or metastatic head and neck cancer in 2017?.J Clin Oncol. 2017; 35: 2229-2231
- Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).J Clin Oncol. 2020; 38: 6502
- De-escalation after DE-ESCALATE and RTOG 1016: A head and neck cancer intergroup framework for future de-escalation studies.J Clin Oncol. 2020; 38: 2552-2557
- Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance.Ann Oncol. 2019; 30: 1638-1646
This work was funded by the National Health and Medical Research Council (Project Grant 1047673 ). Merck KGgA supplied cetuximab and an initial small grant.
Disclosures: D.R. reports grants from Merck Sharp & Dohme, Merck KGaA, Bristol-Myers Squibb, Roche, and Regeneron; grants and personal fees from GSK and MSD; and serving on trial steering committees and/or advisory boards (all uncompensated) for MSD, Merck, Bristol-Myers Squibb, GSK, Regeneron, and Sanofi. M.K. reports grants from Bristol-Myers Squibb. S.P. reports serving on advisory boards for Merck Sharp & Dohme and Merck KGgA and a steering committee for Regeneron. C.W. reports serving on advisory boards for Merck KGgA. B.H. reports grants from Amgen and serving on trial steering committees/advisory boards for Merck Sharp & Dohme, BMS, AstraZeneca, Pfizer, Roche, Eisai, Takeda, and Sanofi. L.M. reports serving on an advisory board for Galera Therapeutics. J. C. reports grants from Merck KGgA and serving on an advisory board for Merck KGgA.
Secondary analyses of these trial data are possible, subject to review by the TROG scientific committee. Once all planned analyses have been completed, de-identified individual participant data and a data dictionary will be made available to the scientific community upon formal application once publication of primary and secondary analyses are complete. All applications will be reviewed as per the Trans Tasman Radiation Oncology Group's policy statement on Undertaking Secondary Analyses on TROG Trials. Approval of applications will be granted by the TROG secondary analysis committee in collaboration with the principal investigator and the trial management committee. Please contact [email protected] for further details on the application procedure or to receive a copy of the study protocol.